These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 1951354)

  • 61. End-stage renal disease in developing countries.
    Kher V
    Kidney Int; 2002 Jul; 62(1):350-62. PubMed ID: 12081600
    [No Abstract]   [Full Text] [Related]  

  • 62. XIII. Analytical methods in ESRD.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S152-76. PubMed ID: 10431012
    [No Abstract]   [Full Text] [Related]  

  • 63. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S124-39. PubMed ID: 10431009
    [No Abstract]   [Full Text] [Related]  

  • 64. The organization and financing of end-stage renal disease in Spain.
    Luño J
    Int J Health Care Finance Econ; 2007 Dec; 7(4):253-67. PubMed ID: 17602295
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Should we limit participation in the ESRD Program?
    Sullivan JD; McGue WF
    Nephrol News Issues; 2012 Jun; 26(7):28, 30-2. PubMed ID: 22928242
    [No Abstract]   [Full Text] [Related]  

  • 66. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
    Ishani A; Guo H; Arneson TJ; Gilbertson DT; Mau LW; Li S; Dunning S; Collins AJ
    J Am Soc Nephrol; 2009 Jul; 20(7):1607-13. PubMed ID: 19389846
    [No Abstract]   [Full Text] [Related]  

  • 67. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: access to ESRD treatments.
    Hörl WH; de Alvaro F; Williams PF
    Nephrol Dial Transplant; 1999; 14 Suppl 6():10-5. PubMed ID: 10528707
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Role of Big Data in the Development and Evaluation of US Dialysis Care.
    Erickson KF; Qureshi S; Winkelmayer WC
    Am J Kidney Dis; 2018 Oct; 72(4):560-568. PubMed ID: 29921451
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Challenges for nephrology practice in Sub-Saharan Africa.
    Naicker S
    Nephrol Dial Transplant; 2010 Mar; 25(3):649-50. PubMed ID: 20067904
    [No Abstract]   [Full Text] [Related]  

  • 70. International comparisons of ESRD therapy.
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):93-5. PubMed ID: 1951362
    [No Abstract]   [Full Text] [Related]  

  • 71. Treatment modalities for ESRD patients. USRDS. United State Renal Data System.
    Am J Kidney Dis; 1997 Aug; 30(2 Suppl 1):S54-66. PubMed ID: 9259693
    [No Abstract]   [Full Text] [Related]  

  • 72. A review of Medicaid rate reductions in 2011.
    Schrag WF
    Nephrol News Issues; 2012 Jan; 26(1):11-2. PubMed ID: 22363948
    [No Abstract]   [Full Text] [Related]  

  • 73. Use of home health care by ESRD and Medicare beneficiaries.
    Kauf TL; Shih YC
    Health Care Financ Rev; 1999; 20(4):127-38. PubMed ID: 11482118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Out-of-network payments for ESRD care: the National Renal Alliance case.
    Riley JB; Soldato D
    Nephrol News Issues; 2008 Jul; 22(8):56, 58. PubMed ID: 18711884
    [No Abstract]   [Full Text] [Related]  

  • 75. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
    Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
    Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The financing and organization of medical care for patients with end-stage renal disease in Sweden.
    Wikström B; Fored M; Eichleay MA; Jacobson SH
    Int J Health Care Finance Econ; 2007 Dec; 7(4):269-81. PubMed ID: 17657602
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The economics of kidney transplantation versus hemodialysis.
    Loubeau PR; Loubeau JM; Jantzen R
    Prog Transplant; 2001 Dec; 11(4):291-7. PubMed ID: 11871278
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Medicare end-stage renal disease program. A report from the Institute of Medicine.
    Levinsky NG; Rettig RA
    N Engl J Med; 1991 Apr; 324(16):1143-8. PubMed ID: 2008193
    [No Abstract]   [Full Text] [Related]  

  • 79. OIG report recommends 9% cut in EPO reimbursement.
    Neumann ME
    Nephrol News Issues; 1992 Dec; 6(12):9, 11, 17. PubMed ID: 1470237
    [No Abstract]   [Full Text] [Related]  

  • 80. The elderly donor.
    Lloveras J
    Transplant Proc; 1991 Oct; 23(5):2592-5. PubMed ID: 1926494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.